CI-930 is a selective, orally active phosphodiesterase 3 ( PDE3 ) inhibitor with an IC 50 value of 0.0.84 μM. CI-930 exerts positive inotropic and vasodilatory effects by inhibiting cAMP hydrolysis. CI-930 also regulates hemodynamics, inhibits the proliferation of coronary artery smooth muscle cells, and suppresses the proliferation of mouse splenocytes. CI-930 can be used in research related to heart failure, atherosclerosis, and asthma.
Products | Products > Disease Areas > Heart Disease | Products > Disease Areas > Asthma | Products > Disease Areas > Atherosclerosis | Products > Disease Areas > Heart Failure | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lower Respiratory Inflammation | Products > Disease Areas > Respiratory Inflammation | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Phosphodiesterase (PDE)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.